Literature DB >> 10896846

Prophylactic surgery decisions and surveillance practices one year following BRCA1/2 testing.

C Lerman1, C Hughes, R T Croyle, D Main, C Durham, C Snyder, A Bonney, J F Lynch, S A Narod, H T Lynch.   

Abstract

BACKGROUND: Although genetic testing for breast cancer risk is clinically available, its impact on health-related behaviors is unknown. This study examined prophylactic surgery and surveillance behavior during the year following BRCA1/2 gene testing.
METHODS: Participants were female members (n = 216) of hereditary breast-ovarian cancer families (84 mutation carriers, 83 noncarriers and 49 test decliners). In this prospective observational study, utilization of prophylactic surgery and surveillance behavior were assessed 1-year following BRCA1/2 testing.
RESULTS: Only 3% of the unaffected carriers obtained prophylactic mastectomy during the 1-year follow-up period. Among the remaining females, carriers had significantly higher rates of mammography (68%) than noncarriers (44%); (OR = 7.1; C.I. = 1.36-37.1; P = 0.02). However, the adherence rate in carriers was unchanged from baseline, suggesting that this difference is attributable to a reduction in screening among noncarriers. Women ages 25-39 years were significantly less likely to obtain mammograms than those aged 40 years and older. Cancer-related distress had a positive but nonsignificant (P < 0.07) association with adherence in bivariate but not multivariate analysis. With regard to ovarian risk, only 13% of carriers obtained prophylactic oophorectomy; of the remaining female carriers, only 21% reported a CA125 and 15% reported a transvaginal ultrasound.
CONCLUSION: The vast majority of BRCA1/2 carriers may not opt for prophylactic surgery, and many do not adhere to surveillance recommendations. Greater attention to risk communication and medical decision-making is warranted. Copyright 2000 American Health Foundation and Academic Press.

Entities:  

Mesh:

Year:  2000        PMID: 10896846     DOI: 10.1006/pmed.2000.0684

Source DB:  PubMed          Journal:  Prev Med        ISSN: 0091-7435            Impact factor:   4.018


  64 in total

Review 1.  The complexities of predictive genetic testing.

Authors:  J P Evans; C Skrzynia; W Burke
Journal:  BMJ       Date:  2001-04-28

Review 2.  Genetic risk and behavioural change.

Authors:  T M Marteau; C Lerman
Journal:  BMJ       Date:  2001-04-28

Review 3.  Genetic testing for lung cancer risk: if physicians can do it, should they?

Authors:  Theodore W Marcy; Michael Stefanek; Kimberly M Thompson
Journal:  J Gen Intern Med       Date:  2002-12       Impact factor: 5.128

4.  Long-term reactions to genetic testing for BRCA1 and BRCA2 mutations: does time heal women's concerns?

Authors:  Chanita Hughes Halbert; Jill E Stopfer; Jasmine McDonald; Benita Weathers; Aliya Collier; Andrea B Troxel; Susan Domchek
Journal:  J Clin Oncol       Date:  2011-10-11       Impact factor: 44.544

5.  Randomized trial finds that prostate cancer genetic risk score feedback targets prostate-specific antigen screening among at-risk men.

Authors:  Aubrey R Turner; Brian R Lane; Dan Rogers; Isaac Lipkus; Kathryn Weaver; Suzanne C Danhauer; Zheng Zhang; Fang-Chi Hsu; Sabrina L Noyes; Tamara Adams; Helga Toriello; Thomas Monroe; Trudy McKanna; Tracey Young; Ryan Rodarmer; Richard J Kahnoski; Mouafak Tourojman; A Karim Kader; S Lilly Zheng; William Baer; Jianfeng Xu
Journal:  Cancer       Date:  2016-07-19       Impact factor: 6.860

6.  Screening behavior in women at increased familial risk for breast cancer.

Authors:  Yoland C Antill; John Reynolds; Mary Anne Young; Judy A Kirk; Katherine M Tucker; Tarli L Bogtstra; Shirley S Wong; Tracy E Dudding; Juliana L Di Iulio; Kelly-Anne Phillips
Journal:  Fam Cancer       Date:  2006-07-07       Impact factor: 2.375

7.  Acceptance of preventive surgeries by Israeli women who had undergone BRCA testing.

Authors:  Vardit Kram; Tamar Peretz; Michal Sagi
Journal:  Fam Cancer       Date:  2006-05-25       Impact factor: 2.375

8.  The process of deciding about prophylactic surgery for breast and ovarian cancer: Patient questions, uncertainties, and communication.

Authors:  Robert Klitzman; Wendy Chung
Journal:  Am J Med Genet A       Date:  2010-01       Impact factor: 2.802

9.  BRCA mutation-negative women from hereditary breast and ovarian cancer families: a qualitative study of the BRCA-negative experience.

Authors:  Alexis D Bakos; Sadie P Hutson; Jennifer T Loud; June A Peters; Ruthann M Giusti; Mark H Greene
Journal:  Health Expect       Date:  2008-09       Impact factor: 3.377

Review 10.  Decision making about cancer screening: an assessment of the state of the science and a suggested research agenda from the ASPO Behavioral Oncology and Cancer Communication Special Interest Group.

Authors:  Marc T Kiviniemi; Jennifer L Hay; Aimee S James; Isaac M Lipkus; Helen I Meissner; Michael Stefanek; Jamie L Studts; John F P Bridges; David R Close; Deborah O Erwin; Resa M Jones; Karen Kaiser; Kathryn M Kash; Kimberly M Kelly; Simon J Craddock Lee; Jason Q Purnell; Laura A Siminoff; Susan T Vadaparampil; Catharine Wang
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-11       Impact factor: 4.254

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.